CO2019004796A2 - Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin - Google Patents
Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatinInfo
- Publication number
- CO2019004796A2 CO2019004796A2 CONC2019/0004796A CO2019004796A CO2019004796A2 CO 2019004796 A2 CO2019004796 A2 CO 2019004796A2 CO 2019004796 A CO2019004796 A CO 2019004796A CO 2019004796 A2 CO2019004796 A2 CO 2019004796A2
- Authority
- CO
- Colombia
- Prior art keywords
- losartan
- rosuvastatin
- preparation
- amlodipine
- pharmaceutical complex
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 5
- 239000002083 C09CA01 - Losartan Substances 0.000 title abstract 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000528 amlodipine Drugs 0.000 title abstract 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004773 losartan Drugs 0.000 title abstract 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
- 229960000672 rosuvastatin Drugs 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una preparación de complejo farmacéutica que incluye amlodipina, losartán y rosuvastatina como ingredientes activos. La preparación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y rosuvastatina como ingredientes activos presenta excelentes características de disolución de todos los ingredientes activos, y también tiene una estabilidad de preparación mejorada. Por lo tanto, la preparación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que ha asegurado la estabilidad de la calidad incluso cuando se almacena durante un largo período de tiempo.The present invention relates to a pharmaceutical complex preparation that includes amlodipine, losartan and rosuvastatin as active ingredients. The pharmaceutical complex preparation of the present invention that includes amlodipine, losartan and rosuvastatin as active ingredients has excellent dissolution characteristics of all active ingredients, and also has improved preparation stability. Therefore, the complex preparation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has ensured the stability of quality even when stored for a long period of time.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160152077 | 2016-11-15 | ||
| PCT/KR2017/012703 WO2018093096A2 (en) | 2016-11-15 | 2017-11-10 | Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019004796A2 true CO2019004796A2 (en) | 2019-05-21 |
Family
ID=62146632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0004796A CO2019004796A2 (en) | 2016-11-15 | 2019-05-10 | Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin |
Country Status (11)
| Country | Link |
|---|---|
| CO (1) | CO2019004796A2 (en) |
| CR (1) | CR20190265A (en) |
| DO (1) | DOP2019000092A (en) |
| EA (1) | EA201991190A1 (en) |
| EC (1) | ECSP19040732A (en) |
| MX (1) | MX2019005230A (en) |
| NI (1) | NI201900048A (en) |
| PH (1) | PH12019500779A1 (en) |
| SG (1) | SG11201903132YA (en) |
| WO (1) | WO2018093096A2 (en) |
| ZA (1) | ZA201902720B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| KR101298788B1 (en) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | A combined formulation with improved stability |
| MX358211B (en) * | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | New differential-release pharmaceutical composition containing three active principles. |
| KR101910901B1 (en) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin |
| KR102369607B1 (en) * | 2014-09-30 | 2022-03-03 | 한미약품 주식회사 | Solid Pharmaceutical Composition Comprising Amlodipine and Losartan |
-
2017
- 2017-11-10 WO PCT/KR2017/012703 patent/WO2018093096A2/en not_active Ceased
- 2017-11-10 MX MX2019005230A patent/MX2019005230A/en unknown
- 2017-11-10 EA EA201991190A patent/EA201991190A1/en unknown
- 2017-11-10 CR CR20190265A patent/CR20190265A/en unknown
- 2017-11-10 SG SG11201903132YA patent/SG11201903132YA/en unknown
-
2019
- 2019-04-11 PH PH12019500779A patent/PH12019500779A1/en unknown
- 2019-04-11 DO DO2019000092A patent/DOP2019000092A/en unknown
- 2019-04-30 ZA ZA2019/02720A patent/ZA201902720B/en unknown
- 2019-05-10 CO CONC2019/0004796A patent/CO2019004796A2/en unknown
- 2019-05-14 NI NI201900048A patent/NI201900048A/en unknown
- 2019-06-11 EC ECSENADI201940732A patent/ECSP19040732A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20190265A (en) | 2019-08-22 |
| DOP2019000092A (en) | 2019-09-30 |
| PH12019500779A1 (en) | 2019-07-29 |
| EA201991190A1 (en) | 2019-10-31 |
| MX2019005230A (en) | 2019-08-14 |
| WO2018093096A3 (en) | 2018-07-26 |
| SG11201903132YA (en) | 2019-05-30 |
| ECSP19040732A (en) | 2019-07-31 |
| WO2018093096A2 (en) | 2018-05-24 |
| NI201900048A (en) | 2019-10-11 |
| ZA201902720B (en) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002269A1 (en) | Allosteric modulators of the hepatitis core protein b. | |
| MX386615B (en) | ADENOASSORTED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS. | |
| MX390001B (en) | STABLE READY-TO-DRINK BEVERAGE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS. | |
| CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
| ECSP19038749A (en) | PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE | |
| UY37342A (en) | COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE | |
| CL2017003437A1 (en) | Solid oral formulation containing irinotecan and method of preparation thereof | |
| CL2017001964A1 (en) | Encapsulation of high power active agents. | |
| MX2017003561A (en) | COMPOSITIONS AND METHODS FOR CANNABINOID COATINGS FOR USE IN THE ADMINISTRATION OF PHARMACOS. | |
| CO2017012645A2 (en) | Antihypertensive agent comprising s-1-propenylcysteine or a salt thereof as active ingredient | |
| IL266279B1 (en) | Aqueous formulations, stability of pexacin for injection and medical uses thereof | |
| CL2018003338A1 (en) | Physiologically balanced injectable formulations of fosnetupitant. | |
| DOP2019000257A (en) | PHARMACEUTICAL COMBINATION INCLUDING PONESIMOD | |
| MX2016015261A (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition thereof. | |
| HUE057871T2 (en) | Hyaluronan conjugates, methods and compositions containing medicinal active ingredients | |
| CO2018002428A2 (en) | Selected amide of gamma-hydroxyiburic acid and uses thereof in the treatment of alcohol abuse | |
| DOP2019000015A (en) | COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE | |
| MX388400B (en) | A TWO-COMPONENT COMPOSITION, COMPRISING ACETYLSALICYLIC ACID. | |
| CO2019004796A2 (en) | Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin | |
| EA201891848A1 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS | |
| PH12016502527A1 (en) | Stabilized desmopressin | |
| UA98822U (en) | APPLICATION OF KAPIKOR (MELDONIUM DIHYDRATE AND γ-BUTYROBETAINE DIHYDRATE) MEDICINE AS THE ENDOTHELIUM PROTECTOR WITH ANTI-ISCHEMIC EFFECT | |
| UA100710U (en) | APPLICATION OF FITOVENOL Capsules AS A HEPATOPROTECTOR |